Corpus callosotomy is a valuable therapeutic option for patients with Lennox–Gastaut syndrome and medically refractory seizures

• The success rate of corpus callosotomy was similar to that in previous reports.
• The complications were also similar to those in previous reports.
• The cost was dramatically lower than that in previous reports.
• This is a feasible treatment option for patients, even for those in developing countries.

PurposeWe present our experience with corpus callosotomy (CC) in a developing country with limited resources in patients with Lennox–Gastaut syndrome (LGS) and medically refractory seizures.MethodsAll patients with LGS who underwent CC for medically refractory epilepsy at Namazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran from May 2009 through March 2012 were reviewed in a retrospective study. Presurgical evaluation included clinical history, neurological examination, a 2-hour video-EEG recording, and 1.5-T MRI. Outcome was evaluated at 6, 12, and 24 months postoperatively. We considered the outcome as a success if the patients were either seizure-free or had more than 85% reduction in seizure frequency compared to their preoperative status.ResultsEighteen patients (14 males and 4 females) had surgery. Overall, seizures in 11 patients (61.1%) responded favorably one year after surgery; this figure was 6 out of 9 patients (66.6%) two years after surgery. Seven patients (38.8%) were free of disabling seizures one year after CC; this figure was three out of nine patients (33.3%) two years after CC. Three patients (16.6%) were free of all seizure types one year after surgery. Ten patients (55.5%) had no postoperative complications of any kind.ConclusionCorpus callosotomy is an effective palliative surgical procedure for patients with LGS with intractable seizures whose seizures are not amenable to focal resection. This is a feasible treatment option for patients, even for those in developing countries with limited resources.